Display options
Cite
Portsmouth SD, Scott CJ. The renaissance of fixed dose combinations: Combivir. Ther Clin Risk Manag. 2007;3(4):579-83
Portsmouth, S. D., & Scott, C. J. (2007). The renaissance of fixed dose combinations: Combivir. Therapeutics and clinical risk management, 3(4), 579-83.
Portsmouth, Simon D, and Scott, Christopher J. "The renaissance of fixed dose combinations: Combivir." Therapeutics and clinical risk management vol. 3,4 (2007): 579-83.
Portsmouth SD, Scott CJ. The renaissance of fixed dose combinations: Combivir. Ther Clin Risk Manag. 2007 Aug;3(4):579-83. PMID: 18472979; PMCID: PMC2374941.
Copy Download .nbib Format: NLM
Share it on

Ther Clin Risk Manag. 2007 Aug;3(4):579-83.

The renaissance of fixed dose combinations: Combivir.

Therapeutics and clinical risk management

Simon D Portsmouth, Christopher J Scott

PMID: 18472979 PMCID: PMC2374941

Abstract

Combivir is a fixed dose combination tablet of two antiretroviral drugs; zidovudine and lamivudine, used in the treatment of HIV-1 infection. AZT was the first antiretroviral used in clinical trials and the addition of lamivudine improved its effectiveness. With the introduction of highly active antiretroviral therapy in the form of a combination of three drugs including two nucleoside analogues, Combivir became the gold standard nucleoside 'backbone' until very recently. Combivir was the first combination agent and simplified HIV therapy greatly. The introduction of newer fixed dose combinations with the advantage of once daily dosing and improved tolerability and toxicity profiles has made Combivir a less popular choice in treatment naïve individuals needing to start therapy.

Keywords: Combivir; HAART; HIV; antiretroviral; lamivudine; zidovudine

References

  1. AIDS. 2004 Apr 30;18(7):1029-36 - PubMed
  2. N Engl J Med. 1997 Nov 20;337(21):1485-90 - PubMed
  3. Proc Natl Acad Sci U S A. 1985 Oct;82(20):7096-100 - PubMed
  4. AIDS. 2006 Apr 4;20(6):795-803 - PubMed
  5. AIDS Res Hum Retroviruses. 2000 Jul 20;16(11):1031-7 - PubMed
  6. J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):535-40 - PubMed
  7. Clin Infect Dis. 2005 Apr 15;40(8):1194-8 - PubMed
  8. J Infect Dis. 1995 Jun;171(6):1438-47 - PubMed
  9. Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5653-6 - PubMed
  10. HIV Med. 2005 May;6(3):185-90 - PubMed
  11. AIDS. 2002 Oct 18;16(15):2087-9 - PubMed
  12. AIDS. 1995 Dec;9(12):1323-9 - PubMed
  13. N Engl J Med. 1994 Nov 3;331(18):1173-80 - PubMed
  14. Lancet. 1996 Aug 3;348(9023):283-91 - PubMed
  15. Clin Infect Dis. 2004 Oct 1;39(7):1038-46 - PubMed
  16. N Engl J Med. 1987 Jul 23;317(4):192-7 - PubMed
  17. J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):484-94 - PubMed
  18. Lancet. 1987 Jan 17;1(8525):132-5 - PubMed
  19. AIDS. 1997 Mar 15;11(4):477-83 - PubMed
  20. Antimicrob Agents Chemother. 1991 Jul;35(7):1386-90 - PubMed
  21. Proc Natl Acad Sci U S A. 1986 Nov;83(21):8333-7 - PubMed
  22. N Engl J Med. 1998 Mar 26;338(13):853-60 - PubMed
  23. N Engl J Med. 1990 Apr 5;322(14):941-9 - PubMed
  24. AIDS. 2000 Feb 18;14(3):F25-32 - PubMed
  25. AIDS. 1992 Dec;6(12):1471-5 - PubMed
  26. N Engl J Med. 1987 Jul 23;317(4):185-91 - PubMed
  27. MMWR Recomm Rep. 2002 Nov 22;51(RR-18):1-38; quiz CE1-4 - PubMed
  28. JAMA. 1996 Jul 10;276(2):118-25 - PubMed
  29. Clin Infect Dis. 2002 Oct 15;35(8):1005-9 - PubMed
  30. Antimicrob Agents Chemother. 2005 Jul;49(7):2648-56 - PubMed
  31. Lancet. 1998 May 23;351(9115):1547-51 - PubMed
  32. J Virol. 2006 May;80(10):4971-7 - PubMed
  33. Lancet. 1994 Apr 9;343(8902):871-81 - PubMed
  34. Lancet. 1986 Mar 15;1(8481):575-80 - PubMed
  35. Antimicrob Agents Chemother. 1993 Jun;37(6):1390-2 - PubMed
  36. Pharmacoepidemiol Drug Saf. 2004 Aug;13(8):537-45 - PubMed
  37. JAMA. 1996 Jul 10;276(2):111-7 - PubMed
  38. N Engl J Med. 2003 Dec 11;349(24):2304-15 - PubMed
  39. N Engl J Med. 2004 Apr 29;350(18):1850-61 - PubMed

Publication Types